155 related articles for article (PubMed ID: 38409962)
1. Decanoylcarnitine Inhibits Triple-Negative Breast Cancer Progression via Mmp9 in an Intermittent Fasting Obesity Mouse.
Tang Y; Chen S; Wang S; Xu K; Zhang K; Wang D; Feng N
Technol Cancer Res Treat; 2024; 23():15330338241233443. PubMed ID: 38409962
[No Abstract] [Full Text] [Related]
2. Luteolin suppresses androgen receptor-positive triple-negative breast cancer cell proliferation and metastasis by epigenetic regulation of MMP9 expression via the AKT/mTOR signaling pathway.
Wu HT; Lin J; Liu YE; Chen HF; Hsu KW; Lin SH; Peng KY; Lin KJ; Hsieh CC; Chen DR
Phytomedicine; 2021 Jan; 81():153437. PubMed ID: 33352494
[TBL] [Abstract][Full Text] [Related]
3. C9orf142 transcriptionally activates MTBP to drive progression and resistance to CDK4/6 inhibitor in triple-negative breast cancer.
Liao L; Deng L; Zhang YL; Yang SY; Andriani L; Hu SY; Zhang FL; Shao ZM; Li DQ
Clin Transl Med; 2023 Nov; 13(11):e1480. PubMed ID: 38009308
[TBL] [Abstract][Full Text] [Related]
4. Flubendazole elicits anti-cancer effects via targeting EVA1A-modulated autophagy and apoptosis in Triple-negative Breast Cancer.
Zhen Y; Zhao R; Wang M; Jiang X; Gao F; Fu L; Zhang L; Zhou XL
Theranostics; 2020; 10(18):8080-8097. PubMed ID: 32724459
[No Abstract] [Full Text] [Related]
5. Circ_0000520 contributes to triple-negative breast cancer progression through mediating the miR-1296/ZFX axis.
Zhou Y; Ma G; Peng S; Tuo M; Li Y; Qin X; Yu Q; Kuang S; Cheng H; Li J
Thorac Cancer; 2021 Sep; 12(18):2427-2438. PubMed ID: 34324278
[TBL] [Abstract][Full Text] [Related]
6. Thymoquinone inhibits cell proliferation, migration, and invasion by regulating the elongation factor 2 kinase (eEF-2K) signaling axis in triple-negative breast cancer.
Kabil N; Bayraktar R; Kahraman N; Mokhlis HA; Calin GA; Lopez-Berestein G; Ozpolat B
Breast Cancer Res Treat; 2018 Oct; 171(3):593-605. PubMed ID: 29971628
[TBL] [Abstract][Full Text] [Related]
7. RNA-binding protein MSI2 isoforms expression and regulation in progression of triple-negative breast cancer.
Li M; Li AQ; Zhou SL; Lv H; Wei P; Yang WT
J Exp Clin Cancer Res; 2020 May; 39(1):92. PubMed ID: 32448269
[TBL] [Abstract][Full Text] [Related]
8. STAT1 Mediates the Transcription of CircIFI30 and Promotes the Progression of Triple-Negative Breast Cancer by Up-Regulating CDCA4.
Zhang J; Xia S; Liu X; Qi D; He X; Chen D
J Environ Pathol Toxicol Oncol; 2022; 41(1):1-13. PubMed ID: 35378000
[TBL] [Abstract][Full Text] [Related]
9. Macrophage migration inhibitory factor inhibition as a novel therapeutic approach against triple-negative breast cancer.
Charan M; Das S; Mishra S; Chatterjee N; Varikuti S; Kaul K; Misri S; Ahirwar DK; Satoskar AR; Ganju RK
Cell Death Dis; 2020 Sep; 11(9):774. PubMed ID: 32943608
[TBL] [Abstract][Full Text] [Related]
10. HIF-1α/Malat1/miR-141 Axis Activates Autophagy to Increase Proliferation, Migration, and Invasion in Triple-negative Breast Cancer.
Xu F; Hu Y; Gao J; Wang J; Xie Y; Sun F; Wang L; Miyamoto A; Xia O; Zhang C
Curr Cancer Drug Targets; 2023; 23(5):363-378. PubMed ID: 36579395
[TBL] [Abstract][Full Text] [Related]
11. Long noncoding RNA ST8SIA6-AS1 promotes cell proliferation and metastasis in triple-negative breast cancer by targeting miR-145-5p/CDCA3 to inactivate the p53/p21 signaling pathway.
Qiao Y; Wang B; Yan Y; Niu L
Environ Toxicol; 2022 Oct; 37(10):2398-2411. PubMed ID: 35730485
[TBL] [Abstract][Full Text] [Related]
12. MiR-6838-5p suppresses cell metastasis and the EMT process in triple-negative breast cancer by targeting WNT3A to inhibit the Wnt pathway.
Liu G; Wang P; Zhang H
J Gene Med; 2019 Dec; 21(12):e3129. PubMed ID: 31693779
[TBL] [Abstract][Full Text] [Related]
13. MicroRNA-211-5p suppresses tumour cell proliferation, invasion, migration and metastasis in triple-negative breast cancer by directly targeting SETBP1.
Chen LL; Zhang ZJ; Yi ZB; Li JJ
Br J Cancer; 2017 Jun; 117(1):78-88. PubMed ID: 28571042
[TBL] [Abstract][Full Text] [Related]
14. ZEB1 induced-upregulation of long noncoding RNA ZEB1-AS1 facilitates the progression of triple negative breast cancer by binding with ELAVL1 to maintain the stability of ZEB1 mRNA.
Luo N; Zhang K; Li X; Hu Y
J Cell Biochem; 2020 Oct; 121(10):4176-4187. PubMed ID: 31922280
[TBL] [Abstract][Full Text] [Related]
15. Calycosin inhibits triple-negative breast cancer progression through down-regulation of the novel estrogen receptor-α splice variant ER-α30-mediated PI3K/AKT signaling pathway.
Li Y; Hu S; Chen Y; Zhang X; Gao H; Tian J; Chen J
Phytomedicine; 2023 Sep; 118():154924. PubMed ID: 37393829
[TBL] [Abstract][Full Text] [Related]
16. Bisdemethoxycurcumin Promotes Apoptosis and Inhibits the Epithelial-Mesenchymal Transition through the Inhibition of the G-Protein-Coupled Receptor 161/Mammalian Target of Rapamycin Signaling Pathway in Triple Negative Breast Cancer Cells.
Chou CH; Wang HK; Lin YC; Tsai DH; Lu MT; Ho CT; Hseu YC; Yang HL; Way TD
J Agric Food Chem; 2021 Dec; 69(48):14557-14567. PubMed ID: 34813306
[TBL] [Abstract][Full Text] [Related]
17. Suppression of KIF3A inhibits triple negative breast cancer growth and metastasis by repressing Rb-E2F signaling and epithelial-mesenchymal transition.
Wang W; Zhang R; Wang X; Wang N; Zhao J; Wei Z; Xiang F; Wang C
Cancer Sci; 2020 Apr; 111(4):1422-1434. PubMed ID: 32011034
[TBL] [Abstract][Full Text] [Related]
18. The circRNA circIFI30 promotes progression of triple-negative breast cancer and correlates with prognosis.
Xing L; Yang R; Wang X; Zheng X; Yang X; Zhang L; Jiang R; Ren G; Chen J
Aging (Albany NY); 2020 Jun; 12(11):10983-11003. PubMed ID: 32497020
[TBL] [Abstract][Full Text] [Related]
19. Hsa_circRNA_102229 facilitates the progression of triple-negative breast cancer via regulating the miR-152-3p/PFTK1 pathway.
Du C; Zhang J; Zhang L; Zhang Y; Wang Y; Li J
J Gene Med; 2021 Sep; 23(9):e3365. PubMed ID: 34031947
[TBL] [Abstract][Full Text] [Related]
20. LINC01096 knockdown inhibits progression of triple-negative breast cancer by increasing miR-3130-3p.
Wang GP; Mou ZL; Xu YY; Liu GX; Wang DM; Zhang HP
Eur Rev Med Pharmacol Sci; 2019 Sep; 23(17):7445-7456. PubMed ID: 31539132
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
